Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
Standard
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. / Fasching, Peter A; Hartkopf, Andreas D; Gass, Paul; Häberle, Lothar; Akpolat-Basci, Leyla; Hein, Alexander; Volz, Bernhard; Taran, Florin-Andrei; Nabieva, Naiba; Pott, Birgit; Overkamp, Friedrich; Einarson, Hanna; Hadji, Peyman; Tesch, Hans; Ettl, Johannes; Lüftner, Diana; Wallwiener, Markus; Müller, Volkmar; Janni, Wolfgang; Fehm, Tanja N; Schneeweiss, Andreas; Untch, Michael; Pott, Dirk; Lux, Michael P; Geyer, Thomas; Liedtke, Cornelia; Seeger, Harald; Wetzig, Sarah; Hartmann, Arndt; Schulz-Wendtland, Rüdiger; Belleville, Erik; Wallwiener, Diethelm; Beckmann, Matthias W; Brucker, Sara Y; Kolberg, Hans-Christian.
in: BREAST CANCER RES TR, Jahrgang 173, Nr. 2, 01.2019, S. 319-328.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
AU - Fasching, Peter A
AU - Hartkopf, Andreas D
AU - Gass, Paul
AU - Häberle, Lothar
AU - Akpolat-Basci, Leyla
AU - Hein, Alexander
AU - Volz, Bernhard
AU - Taran, Florin-Andrei
AU - Nabieva, Naiba
AU - Pott, Birgit
AU - Overkamp, Friedrich
AU - Einarson, Hanna
AU - Hadji, Peyman
AU - Tesch, Hans
AU - Ettl, Johannes
AU - Lüftner, Diana
AU - Wallwiener, Markus
AU - Müller, Volkmar
AU - Janni, Wolfgang
AU - Fehm, Tanja N
AU - Schneeweiss, Andreas
AU - Untch, Michael
AU - Pott, Dirk
AU - Lux, Michael P
AU - Geyer, Thomas
AU - Liedtke, Cornelia
AU - Seeger, Harald
AU - Wetzig, Sarah
AU - Hartmann, Arndt
AU - Schulz-Wendtland, Rüdiger
AU - Belleville, Erik
AU - Wallwiener, Diethelm
AU - Beckmann, Matthias W
AU - Brucker, Sara Y
AU - Kolberg, Hans-Christian
PY - 2019/1
Y1 - 2019/1
N2 - PURPOSE: Neoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM). This analysis was aimed at real-world validation of these results from prospective randomized trials.METHODS: In a retrospective analysis conducted in the PRAEGNANT network, patients were eligible for inclusion if they had either received neoadjuvant therapy with CTX/TZM or chemotherapy, trastuzumab, and pertuzumab (CTX/TZM/PTZ) and subsequently underwent surgery for their primary breast cancer. The effect of the two neoadjuvant regimens on pCR in addition to commonly applicable predictors of pCR was analyzed in 300 patients from three study sites, using logistic regression analyses with treatment arm, age, clinical tumor stage, grading, and hormone receptor status as predictors.RESULTS: pCR with complete disappearance of all tumor cells was seen in 30.2% (n = 58) of patients treated with CTX/TZM and in 52.8% (n = 57) of those treated with CTX/TZM/PTZ. CTX/TZM/PTZ was positively associated with pCR (adjusted odds ratio 2.44; 95% CI 1.49-4.02). Mastectomy rates were not influenced by the therapy.CONCLUSIONS: The results of clinical trials were confirmed in this dataset of patients who were treated outside of clinical trials in everyday routine work. pCR rates can be improved by 20% with pertuzumab in routine clinical use.
AB - PURPOSE: Neoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM). This analysis was aimed at real-world validation of these results from prospective randomized trials.METHODS: In a retrospective analysis conducted in the PRAEGNANT network, patients were eligible for inclusion if they had either received neoadjuvant therapy with CTX/TZM or chemotherapy, trastuzumab, and pertuzumab (CTX/TZM/PTZ) and subsequently underwent surgery for their primary breast cancer. The effect of the two neoadjuvant regimens on pCR in addition to commonly applicable predictors of pCR was analyzed in 300 patients from three study sites, using logistic regression analyses with treatment arm, age, clinical tumor stage, grading, and hormone receptor status as predictors.RESULTS: pCR with complete disappearance of all tumor cells was seen in 30.2% (n = 58) of patients treated with CTX/TZM and in 52.8% (n = 57) of those treated with CTX/TZM/PTZ. CTX/TZM/PTZ was positively associated with pCR (adjusted odds ratio 2.44; 95% CI 1.49-4.02). Mastectomy rates were not influenced by the therapy.CONCLUSIONS: The results of clinical trials were confirmed in this dataset of patients who were treated outside of clinical trials in everyday routine work. pCR rates can be improved by 20% with pertuzumab in routine clinical use.
KW - Journal Article
KW - Datasets as Topic
KW - Prospective Studies
KW - Humans
KW - Middle Aged
KW - Antibodies, Monoclonal, Humanized/therapeutic use
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Breast Neoplasms/mortality
KW - Disease-Free Survival
KW - Trastuzumab/therapeutic use
KW - Mastectomy
KW - Adult
KW - Female
KW - Aged
KW - Retrospective Studies
KW - Neoadjuvant Therapy/methods
U2 - 10.1007/s10549-018-5008-3
DO - 10.1007/s10549-018-5008-3
M3 - SCORING: Journal article
C2 - 30324275
VL - 173
SP - 319
EP - 328
JO - BREAST CANCER RES TR
JF - BREAST CANCER RES TR
SN - 0167-6806
IS - 2
ER -
